https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Restenosis remains a limitation of endovascular angioplasty with a patency of 30% in BTK at 12months. Several studies on drug-coated balloons have not demonstrated any improvements in terms of patency and target lesions revascularization in BTK lesions. This prospective single-centre cohort study evaluates the safety and efficacy of a new generation low-dose drug-coated balloon (DC with a reduced crystalline structure to treat below the knee (BTK) lesions in patients with critical limb ischemia (CLI). Between November 201
Aimer
Commentaire
Partagez
